Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels

Journal of Clinical Oncology

Volumn 35, Issue 16, 2017, Pages 1803-1813

  Kochenderfer, James N ^a   Somerville, Robert P T ^a   Lu, Tangying ^a   Shi, Victoria ^a   Bot, Adrian ^b   Rossi, John ^b   Xue, Allen ^b   Goff, Stephanie L ^a   Yang, James C ^a   Sherry, Richard M ^a   Klebanoff, Christopher A ^a   Kammula, Udai S ^a   Sherman, Marika ^b   Perez, Arianne ^b   Yuan, Constance M ^a   Feldman, Tatyana ^c   Friedberg, Jonathan W ^d   Roschewski, Mark J ^a   Feldman, Steven A ^a   McIntyre, Lori ^a   Toomey, Mary Ann ^a   Rosenberg, Steven A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Kite Pharma   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR 19; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HEMOGLOBIN; HYPERTENSIVE AGENT; INTERLEUKIN 15; TOCILIZUMAB; UNCLASSIFIED DRUG; IL15 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; VIDARABINE;

ADULT; AGED; AGITATION; ARTICLE; ATAXIA; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CATHETER INFECTION; CELL TRANSFER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DIFFUSE LARGE B CELL LYMPHOMA; DRUG SYNTHESIS; DRUG TARGETING; DYSPHAGIA; DYSPHASIA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPONATREMIA; HYPOTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MOTOR NEUROPATHY; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPHIL COUNT; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; T LYMPHOCYTE; THROMBOCYTE COUNT; TREMOR; URINARY TRACT INFECTION; URINE INCONTINENCE; VISUAL IMPAIRMENT; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; BLOOD; IMMUNOLOGY; LYMPHOMA; PROCEDURES; TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

ADULT; AGED; ANTIGENS, CD19; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; LYMPHOMA; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 85017643829     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.3024     Document Type: Article

References (54)

1. Sadelain M: CAR therapy: The CD19 paradigm. J Clin Invest 125:3392-3400, 2015
2. Dotti G, Gottschalk S, Savoldo B, et al: Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257: 107-126, 2014
3. McLaughlin L, Cruz CR, Bollard CM: Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: Current strategies and recent advances. Ther Adv Hematol 6:295-307, 2015
4. Kebriaei P, Singh H, Huls MH, et al: Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126:3363-3376, 2016
5. Kochenderfer JN, Rosenberg SA: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10: 267-276, 2013
6. Cruz CR, Micklethwaite KP, Savoldo B, et al: Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 122:2965-2973, 2013
7. Savoldo B, Ramos CA, Liu E, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822-1826, 2011
8. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
9. Brentjens RJ, Latouche JB, Santos E, et al: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286, 2003
10. Cooper LJ, Topp MS, Serrano LM, et al: T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637-1644, 2003
11. Carpenter RO, Evbuomwan MO, Pittaluga S, et al: B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 19:2048-2060, 2013
12. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
13. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-528, 2015
14. Brentjens RJ, Davila ML, Riviere I, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013
15. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25, 2014
16. Turtle CJ, Hanafi LA, Berger C, et al: CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126: 2123-2138, 2016
17. Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011:498-505, 2011
18. Martelli M, Ferreri AJM, Agostinelli C, et al: Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87:146-171, 2013
19. Kochenderfer JN, Wilson WH, Janik JE, et al: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102, 2010
20. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012
21. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549, 2015
22. Turtle CJ, Hanafi LA, Berger C, et al: Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8: 355ra116, 2016
23. Elstrom RL, Martin P, Ostrow K, et al: Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: Implications for the development of novel therapeutic strategies. Clin Lymphoma Mye-loma Leuk 10:192-196, 2010
24. Moore S, Kayani I, Peggs K, et al: Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol 157:543-552, 2012
25. Crump M, Neelapu SS, Farooq U, et al: Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol 34, 2016 (suppl; abstr 7516)
26. Nagle SJ, Woo K, Schuster SJ, et al: Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rit-uximab era. Am J Hematol 88:890-894, 2013
27. Vose JM, Bierman PJ, Anderson JR, et al: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood 80: 2142-2148, 1992
28. Brudno JN, Kochenderfer JN: Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 127:3321-3330, 2016
29. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063-1074, 1982
30. Gattinoni L, Finkelstein SE, Klebanoff CA, et al: Removal of homeostatic cytokine sinks by lympho-depletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912, 2005
31. Kochenderfer JN, Yu Z, Frasheri D, et al: Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116:3875-3886, 2010
32. Waldmann TA: Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol 10:1689-1701, 2014
33. Pilipow K, Roberto A, Roederer M, et al: IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res 75:5187-5193, 2015
34. Mishra A, Sullivan L, Caligiuri MA: Molecular pathways: Interleukin-15 signaling in health and in cancer. Clin Cancer Res 20:2044-2050, 2014
35. Kochenderfer JN, Feldman SA, Zhao Y, et al: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32: 689-702, 2009
36. Kochenderfer JN, Dudley ME, Carpenter RO, et al: Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-4139, 2013
37. O’Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
38. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
39. Hamlin PA, Zelenetz AD, Kewalramani T, et al: Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003
40. Sallusto F, Lenig D, Förster R, et al: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712, 1999
41. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 17:3128-3135, 1999
42. Bishop RJ, Ding X, Heller CK III, et al: Rapid vision loss associated with fludarabine administration. Retina 30:1272-1277, 2010
43. Oft M: IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res 2:194-199, 2014
44. Fujii S, Shimizu K, Shimizu T, et al: Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98:2143-2151, 2001
45. Emmerich J, Mumm JB, Chan IH, et al: IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72:3570-3581, 2012
46. Brudno JN, Somerville RP, Shi V, et al: Allo-geneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34:1112-1121, 2016
47. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
48. Xu Y, Zhang M, Ramos CA, et al: Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123:3750-3759, 2014
49. Hoyos V, Savoldo B, Quintarelli C, et al: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24:1160-1170, 2010
50. Klebanoff CA, Finkelstein SE, Surman DR, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101:1969-1974, 2004
51. Hoyos V, Savoldo B, Quintarelli C, et al: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24:1160-1170, 2010
52. Roychowdhury S, May KF Jr, Tzou KS, et al: Failed adoptive immunotherapy with tumor-specific T cells: Reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 64:8062-8067, 2004
53. Miller JS, Rooney CM, Curtsinger J, et al: Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: Implications for clinical therapy. Biol Blood Marrow Transplant 20:1252-1257, 2014
54. Wang T, Lee MH, Choi E, et al: Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS One 7: e43950, 2012